Results 11 to 20 of about 208,301 (303)
Structure, 2017 Mutations in members of the RAS family of small GTPases have been associated with numerous human cancers. However, RAS family members are notoriously difficult to target. In this issue of Structure, Lu et al. (2017) examine the effects of two compounds with distinct chemical scaffolds on the structure and dynamics of an oncogenic KRAS mutant, thus ...
Daniel J, Deredge, Patrick L, Wintrode
openaire +2 more sources
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
Cancers, 2021 Activating mutations in KRAS are present in 25% of human cancers. When mutated, the KRAS protein becomes constitutively active, stimulating various effector pathways and leading to the deregulation of key cellular processes, including the suppression of apoptosis and enhancement of proliferation.
Yuta Adachi +3 more
openaire +3 more sources
Cold Spring Harbor Perspectives in Medicine, 2018 Oncogenic Kras are genetic dependencies for the majority of pancreatic and colorectal adenocarcinomas; however, much remains to be understood regarding its tropism to these carcinomas. Recently developed organoid technology presents a more representative model culture system for pancreatic and colon epithelial tissues as well as better fostering the ...
Derek, Cheng, David, Tuveson
openaire +2 more sources
KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations [PDF]
Genes & Cancer, 2011 KRAS is a potent oncogene and is mutated in about 30% of all human cancers. However, the biological context of KRAS-dependent oncogenesis is poorly understood. Genetically engineered mouse models of cancer provide invaluable tools to study the oncogenic process, and insights from KRAS-driven models have significantly increased our understanding of the ...
Rónán C, O'Hagan, Joerg, Heyer
openaire +2 more sources
Сибирский онкологический журнал, 2020 Purpose: to evaluate the effect of somatic mutations of the KRAS, NRAS, BRAF genes and the status of microsatellite instability on the overall and disease-free survival of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal ...
V. P. Shubin +6 more
doaj +1 more source
Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials [PDF]
, 2012 Purpose: This study investigated the impact of specific mutations in codon 12 of the Kirsten-ras (KRAS) gene on treatment efficacy in patients with metastatic colorectal cancer (mCRC).
Allegra CJ +41 more
core +1 more source
Roczniki Historyczne, 2014 „Wie sollen die Füchse im Weinberg des Herrn gefangen werden?” Antihäretische Inhalte in den Predigten Bernhards von Clairvaux und Helinands von Froidmont Zusammenfassung Seit der Mitte des 12.
Paweł Kras
doaj +1 more source
Case Reports in Dermatology, 2021 We present a case of malignant melanoma (MM) developing within a vascular malformation showing features of cellular blue nevi. A 47-year-old male presented with acute symptoms of a temporal and zygomatic mass, which were both previously asymptomatic upon
Felicia Tai +5 more
doaj +1 more source
Detection of activating mutations in RAS/RAF/MEK/ERK and JAK/STAT signaling pathways [PDF]
Терапевтический архив, 2020 Issue.The study of activating mutations (NRAS,KRAS,FLT3,JAK2,CRLF2genes) of RAS/RAF/MEK/ERK and JAK/STAT signaling pathways in B-cell acute lymphoblastic leukemia (B-ALL) in adult patients which are included in Russian multicenter clinical trials ...
K. I. Zarubina +13 more
doaj +1 more source
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer [PDF]
, 2017 KRAS mutated tumours represent a large fraction of human cancers, but the vast majority remains refractory to current clinical therapies. Thus, a deeper understanding of the molecular mechanisms triggered by KRAS oncogene may yield alternative ...
Andersen, Jesper B. +22 more
core +3 more sources